HPGC Renmintongtai Pharmaceutical Corporation (SHA:600829)
China · Delayed Price · Currency is CNY 9.76
-0.20 (-2.01%)
Sep 10, 2026, 11:29 AM CST
SHA:600829 Revenue
HPGC Renmintongtai Pharmaceutical had revenue of 2.58B CNY in the quarter ending June 30, 2026, with 4.10% growth. This brings the company's revenue in the last twelve months to 10.64B, up 4.17% year-over-year. In the year 2025, HPGC Renmintongtai Pharmaceutical had annual revenue of 10.38B with 3.29% growth.
Revenue (ttm)
10.64B
Revenue Growth
+4.17%
P/S Ratio
0.54
Revenue / Employee
3.89M
Employees
2,735
Market Cap
5.78B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.38B | 330.43M | 3.29% |
| Dec 31, 2024 | 10.05B | -341.70M | -3.29% |
| Dec 31, 2023 | 10.39B | 748.89M | 7.77% |
| Dec 31, 2022 | 9.64B | 325.86M | 3.50% |
| Dec 31, 2021 | 9.32B | 1.31B | 16.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.